Terray Therapeutics, a biotechnology company integrating scale experimentation and generative AI to improve the speed, cost, and success rate of small molecule drug discovery and development, announced a multi-target collaboration agreement with Bristol Myers Squibb to discover and develop small molecule therapeutics in certain disease areas.
Under the terms of the agreement, Terray will discover and develop small molecule compounds against a set of targets nominated by Bristol Myers Squibb using the Terray tNova platform, with Bristol Myers Squibb subsequently assuming responsibility for development and commercialization. Terray will receive an upfront payment and is eligible to receive milestone payments associated with the achievement of preclinical, clinical, and sales milestones as well as tiered royalties on net sales of products commercialized by Bristol Myers Squibb in connection with the collaboration.
Terray's platform is built for generative AI-driven drug discovery, integrating chemical experimentation and computation. Everything the company does is grounded in an iterative approach, producing massive amounts of precise, purpose-built data that enables generative optimization of small molecules—all in service of finding the right molecules to solve complex problems in drug discovery.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!